JP2022523819A5 - - Google Patents
Info
- Publication number
- JP2022523819A5 JP2022523819A5 JP2021552742A JP2021552742A JP2022523819A5 JP 2022523819 A5 JP2022523819 A5 JP 2022523819A5 JP 2021552742 A JP2021552742 A JP 2021552742A JP 2021552742 A JP2021552742 A JP 2021552742A JP 2022523819 A5 JP2022523819 A5 JP 2022523819A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oil
- pharmaceutically acceptable
- abiraterone
- decanoate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814568P | 2019-03-06 | 2019-03-06 | |
| US62/814,568 | 2019-03-06 | ||
| US201962849259P | 2019-05-17 | 2019-05-17 | |
| US62/849,259 | 2019-05-17 | ||
| PCT/US2020/020915 WO2020180942A1 (en) | 2019-03-06 | 2020-03-04 | Abiraterone prodrugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523819A JP2022523819A (ja) | 2022-04-26 |
| JP2022523819A5 true JP2022523819A5 (enExample) | 2023-03-09 |
| JP7644713B2 JP7644713B2 (ja) | 2025-03-12 |
Family
ID=70190090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552742A Active JP7644713B2 (ja) | 2019-03-06 | 2020-03-04 | アビラテロンプロドラッグ |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10792292B2 (enExample) |
| EP (2) | EP3935068B1 (enExample) |
| JP (1) | JP7644713B2 (enExample) |
| KR (1) | KR102879575B1 (enExample) |
| CN (3) | CN120531742A (enExample) |
| AU (1) | AU2020232706B2 (enExample) |
| BR (1) | BR112021017377A2 (enExample) |
| CA (1) | CA3131034A1 (enExample) |
| DK (1) | DK3935068T3 (enExample) |
| ES (1) | ES2964818T3 (enExample) |
| IL (1) | IL286048B2 (enExample) |
| MX (1) | MX2021010553A (enExample) |
| PL (1) | PL3935068T3 (enExample) |
| WO (1) | WO2020180942A1 (enExample) |
| ZA (1) | ZA202107278B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7644713B2 (ja) * | 2019-03-06 | 2025-03-12 | プロペラ セラピューティクス インコーポレイテッド | アビラテロンプロドラッグ |
| US12347562B2 (en) * | 2019-12-26 | 2025-07-01 | Cerner Innovation, Inc. | Decision support application for PCOS |
| JP7850366B2 (ja) * | 2020-09-02 | 2026-04-23 | アステラス ユーエス エルエルシー | アビラテロンプロドラッグ |
| CN113929727A (zh) * | 2020-09-28 | 2022-01-14 | 南京易腾药物研究院有限公司 | 阿比特龙酯类衍生物及其制备方法和应用 |
| CA3207282A1 (en) * | 2021-02-15 | 2022-08-18 | Matthew J. Sharp | Abiraterone prodrugs |
| CN113061154B (zh) * | 2021-03-25 | 2022-07-08 | 天津海润家和创新医药研究有限责任公司 | 新型注射用阿比特龙衍生物的制备方法和用途 |
| CN113527401A (zh) * | 2021-08-26 | 2021-10-22 | 雷昊言 | 一种阿比特龙前体化合物及其制备方法和应用 |
| CN118215466A (zh) | 2021-09-08 | 2024-06-18 | 普洛佩拉治疗公司 | 口服阿比特龙制剂 |
| KR20240167653A (ko) | 2022-03-01 | 2024-11-27 | 프로펠라 쎄라퓨틱스, 인크. | 아비라테론 데카노에이트 프로드러그 및 요법에서의 용도 |
| WO2024107928A1 (en) | 2022-11-16 | 2024-05-23 | Propella Therapeutics, Inc. | Abiraterone decanoate composition and use in therapy |
| CN116046950A (zh) * | 2023-01-18 | 2023-05-02 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种检测醋酸阿比特龙中5种杂质的方法 |
| LU506495B1 (en) * | 2024-03-01 | 2025-09-01 | Alfasan Nederland B V | 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| JP2004002321A (ja) * | 2002-03-11 | 2004-01-08 | Takeda Chem Ind Ltd | 性ホルモン依存性疾患治療剤 |
| EP1488807A4 (en) | 2002-03-11 | 2009-07-08 | Takeda Pharmaceutical | MEANS FOR THE TREATMENT OF SEXUAL-HORMONE-RELATED DISEASES |
| TW200404552A (en) | 2002-05-30 | 2004-04-01 | Akzo Nobel Nv | Self administered contraception |
| GB0418900D0 (en) | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
| JP5235662B2 (ja) | 2005-06-16 | 2013-07-10 | ミリアド ジェネティクス， インコーポレイテッド | 薬学的組成物およびその使用 |
| PL2061561T3 (pl) | 2006-08-25 | 2013-12-31 | Janssen Oncology Inc | Kompozycje do leczenia raka |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| US20090124587A1 (en) | 2007-07-12 | 2009-05-14 | Auerbach Alan H | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS |
| US8791095B2 (en) | 2009-02-05 | 2014-07-29 | Tokai Pharmaceuticals, Inc. | Steroidal CYP17 inhibitors/antiandrogens |
| WO2010091306A1 (en) | 2009-02-05 | 2010-08-12 | Tokai Pharmaceuticals | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| EP2506855A4 (en) | 2009-11-30 | 2014-07-30 | Harbor Biosciences Inc | ANTICARCINOMA COMPOUNDS AND SCREENING METHODS |
| WO2011083830A1 (ja) | 2010-01-06 | 2011-07-14 | 学校法人関西文理総合学園 | 新規抗がん剤およびそのスクリーニング方法 |
| CA2819515A1 (en) | 2010-12-16 | 2012-06-21 | Biomarin Pharmaceutical Inc. | Cyp11b, cyp17, and/or cyp21 inhibitors |
| DE102011083725A1 (de) | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| JP6091510B2 (ja) | 2011-10-10 | 2017-03-08 | ザック システム | １７−置換ステロイドの製造方法 |
| PT2785349T (pt) | 2011-11-30 | 2019-12-11 | Astrazeneca Ab | Tratamento combinado de cancro |
| AU2012358219A1 (en) | 2011-12-22 | 2014-07-10 | Tokai Pharmaceuticals, Inc. | Methods and compositions for combination therapy using P13K/mTOR inhibitors |
| US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| CA2871314A1 (en) | 2012-04-23 | 2013-10-31 | Alphora Research Inc. | Process for preparation of 17-substituted steroids |
| WO2014009434A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
| EP2877482A4 (en) | 2012-07-25 | 2016-04-06 | Mapi Pharma Ltd | PROCESS AND INTERMEDIATES USED IN THE PREPARATION OF ABIRATERONE ACETATE |
| US20140011992A1 (en) | 2012-12-20 | 2014-01-09 | Crystal Pharma, S.A.U. | Synthesis of abiraterone and related compounds |
| DK2945628T3 (da) | 2013-01-15 | 2020-05-04 | Aragon Pharmaceuticals Inc | Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer |
| US20150337003A1 (en) | 2013-01-18 | 2015-11-26 | Cortendo Ab (Publ) | Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction |
| US20150246060A1 (en) | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
| EP2969227B1 (en) | 2013-03-15 | 2019-05-08 | Iceutica Inc. | Abiraterone acetate formulation |
| EP3035938B1 (en) | 2013-09-10 | 2020-08-19 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
| AU2014330779A1 (en) | 2013-10-01 | 2016-04-07 | Novartis Ag | Combination |
| CN106456795A (zh) | 2014-03-03 | 2017-02-22 | 辛塔医药品有限公司 | 靶向治疗学 |
| EP3131586A4 (en) | 2014-03-18 | 2017-10-25 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| CN104017045B (zh) * | 2014-06-23 | 2016-01-13 | 广州艾格生物科技有限公司 | 甾体cyp17抑制剂的新型药物前体及其应用、制备方法 |
| US9937259B2 (en) | 2014-06-27 | 2018-04-10 | Zhuhai Beihai Biotech Co., Ltd. | Abiraterone derivatives and non-covalent complexes with albumin |
| BR112017003219A2 (pt) | 2014-09-18 | 2017-11-28 | Iceutica Inc | formulação de acetato de abiraterona e métodos de uso |
| CN104356191A (zh) | 2014-09-29 | 2015-02-18 | 上海延安药业（湖北）有限公司 | 阿比特龙单琥珀酸酯及其制备方法 |
| WO2016082792A1 (zh) | 2014-11-28 | 2016-06-02 | 四川海思科制药有限公司 | 一种阿比特龙衍生物及其制备方法和医药用途 |
| CN104447394B (zh) * | 2014-12-17 | 2017-01-18 | 成都傲飞生物化学品有限责任公司 | 一种乌苯美司的新型合成工艺 |
| CN104710499A (zh) | 2015-02-15 | 2015-06-17 | 重庆医药工业研究院有限责任公司 | 一种丙酸阿比特龙的晶型及其制备方法 |
| CN108112235A (zh) | 2015-03-06 | 2018-06-01 | 克利夫兰临床基金会 | 改变类固醇代谢以用于治疗类固醇依赖性疾病 |
| CA3008909C (en) | 2015-12-23 | 2023-10-03 | The University Of British Columbia | Lipid-linked prodrugs |
| JP6842474B2 (ja) | 2016-02-02 | 2021-03-17 | 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． | ステロイド系化合物、当該化合物を含む組成物及びその使用 |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| CN109922809B (zh) | 2016-10-11 | 2021-08-13 | 珠海贝海生物技术有限公司 | 阿比特龙衍生物及其制剂 |
| CN106977577A (zh) | 2017-04-21 | 2017-07-25 | 湖南师范大学 | 两类阿比特龙衍生物的合成 |
| CN113473974A (zh) | 2019-01-25 | 2021-10-01 | 深圳市药欣生物科技有限公司 | 药物组合物 |
| JP7644713B2 (ja) | 2019-03-06 | 2025-03-12 | プロペラ セラピューティクス インコーポレイテッド | アビラテロンプロドラッグ |
| EP3941478A4 (en) | 2019-03-18 | 2022-12-28 | Dispersol Technologies, LLC | PHARMACEUTICAL FORMULATIONS OF ABIRATERON CYCLIC OLIGOMERS AND METHODS OF PREPARATION AND ADMINISTRATION THEREOF |
| JP7850366B2 (ja) | 2020-09-02 | 2026-04-23 | アステラス ユーエス エルエルシー | アビラテロンプロドラッグ |
| CN113929727A (zh) | 2020-09-28 | 2022-01-14 | 南京易腾药物研究院有限公司 | 阿比特龙酯类衍生物及其制备方法和应用 |
| CA3207282A1 (en) | 2021-02-15 | 2022-08-18 | Matthew J. Sharp | Abiraterone prodrugs |
| CN118215466A (zh) | 2021-09-08 | 2024-06-18 | 普洛佩拉治疗公司 | 口服阿比特龙制剂 |
-
2020
- 2020-03-04 JP JP2021552742A patent/JP7644713B2/ja active Active
- 2020-03-04 CN CN202510025166.7A patent/CN120531742A/zh active Pending
- 2020-03-04 US US16/808,912 patent/US10792292B2/en active Active
- 2020-03-04 CA CA3131034A patent/CA3131034A1/en active Pending
- 2020-03-04 PL PL20717363.4T patent/PL3935068T3/pl unknown
- 2020-03-04 BR BR112021017377A patent/BR112021017377A2/pt unknown
- 2020-03-04 IL IL286048A patent/IL286048B2/en unknown
- 2020-03-04 WO PCT/US2020/020915 patent/WO2020180942A1/en not_active Ceased
- 2020-03-04 EP EP20717363.4A patent/EP3935068B1/en active Active
- 2020-03-04 CN CN202510025122.4A patent/CN120484046A/zh active Pending
- 2020-03-04 EP EP23188119.4A patent/EP4286006A3/en active Pending
- 2020-03-04 MX MX2021010553A patent/MX2021010553A/es unknown
- 2020-03-04 DK DK20717363.4T patent/DK3935068T3/da active
- 2020-03-04 CN CN202080032112.9A patent/CN114026106B/zh active Active
- 2020-03-04 KR KR1020217032021A patent/KR102879575B1/ko active Active
- 2020-03-04 AU AU2020232706A patent/AU2020232706B2/en active Active
- 2020-03-04 ES ES20717363T patent/ES2964818T3/es active Active
- 2020-08-10 US US16/989,304 patent/US11559534B2/en active Active
-
2021
- 2021-09-28 ZA ZA2021/07278A patent/ZA202107278B/en unknown
-
2023
- 2023-01-19 US US18/098,798 patent/US12138273B2/en active Active
-
2024
- 2024-10-18 US US18/920,358 patent/US20250099489A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286048B1 (en) | Abiraterone decanoate and pharmaceutically acceptable salts thereof, pharmaceutical compsitions comprising the same, uses and preparation thereof | |
| US9388210B2 (en) | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| TWI641616B (zh) | 阿比特龍衍生物及其製備方法和醫藥用途 | |
| JP2024506382A5 (enExample) | ||
| US11111227B2 (en) | Rotigotine behenate, and manufacturing method and application thereof | |
| US20030092638A1 (en) | Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents | |
| JP2019514955A (ja) | 選択的エストロゲン受容体ダウンレギュレーター（ｓｅｒｄｓ） | |
| WO2014127201A1 (en) | Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for gaba type-a receptors | |
| JP2018138594A (ja) | オナプリストン多形体及び使用方法 | |
| JP2021522306A (ja) | ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形 | |
| CN113929727A (zh) | 阿比特龙酯类衍生物及其制备方法和应用 | |
| JP2014516078A (ja) | 新規なタッカロノリド微小管安定剤 | |
| JPS6341887B2 (enExample) | ||
| CA2626627C (en) | Androsterone derivatives and method of use thereof | |
| RU2021128701A (ru) | Пролекарства абиратерона | |
| AU2004243500A1 (en) | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases | |
| WO2014169462A1 (zh) | 具有抗癌活性的7-α-[9-(4,4,5,5,-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇的酯类衍生物及其制备方法 | |
| US20030069215A1 (en) | Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate | |
| TW200904451A (en) | Progesterone-receptor antagonist for use in BRCA alone or as combination with antiestrogen | |
| CN104997788B (zh) | 一种抗抑郁化合物在制备抗抑郁药物和抗抑郁保健食品中的应用 | |
| JPH01500111A (ja) | １１−デスオキシ−１７α−ヒドロキシコルチコステロン誘導体 | |
| TW200902028A (en) | Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases | |
| RU2719457C2 (ru) | Сложные эфиры стероидного лактама и производных бис(2-хлорэтил)аминофеноксипропановой кислоты | |
| CN103664836B (zh) | 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法 | |
| JPH0240079B2 (enExample) |